Recombinant Human Activin A receptor, type IIB (RIIB)

Recombinant Human Activin A receptor, type IIB (RIIB) is widely used in research applications due to its critical role in mediating signaling for the transforming growth factor-beta (TGF-β) superfamily, particularly activin A and myostatin, which regulate cell growth, differentiation, and muscle mass.

Key scientific reasons to use recombinant RIIB in research include:

• High Affinity Ligand Binding: RIIB displays a 3- to 4-fold higher affinity for activin A compared to type II receptors, making it a potent tool for studying ligand-receptor interactions and for use as an activin antagonist in functional assays.

• Signal Transduction Studies: RIIB is essential for ligand binding and forms a stable complex with type I receptors, leading to phosphorylation and activation of downstream SMAD signaling pathways. This is fundamental for dissecting TGF-β/activin signaling mechanisms in cellular models.

• Muscle Biology and Therapeutic Research: Blocking or modulating RIIB signaling has been shown to increase skeletal muscle mass and improve muscle function, as demonstrated in models of muscular dystrophy and cachexia. Recombinant RIIB is used to study these pathways and develop therapeutic strategies for muscle-wasting diseases.

• Bone Formation and Disease Models: RIIB is involved in bone formation and is implicated in diseases such as osteoporosis and osteogenesis imperfecta. Recombinant RIIB can be used to investigate these processes and screen for potential therapeutic agents.

• Inflammation and Autoimmunity: RIIB-mediated signaling is relevant in inflammatory and autoimmune disorders, including systemic lupus erythematosus and rheumatoid arthritis, making recombinant RIIB valuable for immunological research and drug screening.

• Structural and Biochemical Analysis: Recombinant RIIB enables detailed structural studies (e.g., crystallography) to understand kinase domain architecture, substrate specificity, and to design selective inhibitors for intracellular signaling.

Typical research applications include:

• Ligand-binding assays (e.g., ELISA, SPR) to quantify interactions with activin A, myostatin, and related ligands.
• Cell signaling studies to elucidate downstream effects of receptor activation or inhibition.
• Functional screening for inhibitors or therapeutic candidates targeting muscle growth, bone formation, or immune modulation.
• Structural biology for rational drug design and mechanistic insights.

In summary, recombinant RIIB is a versatile reagent for investigating TGF-β superfamily signaling, muscle and bone biology, immune regulation, and for screening potential therapeutic agents in various disease models.

Recombinant Human Activin A receptor, type IIB (RIIB) can be used as a standard for quantification or calibration in ELISA assays, but only under specific conditions and with careful validation. The suitability depends on the assay design, the analyte being measured, and the compatibility of the recombinant protein with the antibodies and detection system used in your ELISA.

Key considerations:

• Assay Target: If your ELISA is designed to quantify Activin A receptor, type IIB (ACVR2B) itself (not Activin A ligand), recombinant ACVR2B can serve as a standard, provided it is structurally and immunologically similar to the native protein in your samples. Many commercial ELISA kits for ACVR2B use recombinant protein as the standard, and these kits are validated to recognize both natural and recombinant forms.

• Assay Type: For sandwich ELISAs targeting ACVR2B, recombinant ACVR2B is commonly used to generate the standard curve, allowing quantification of ACVR2B in biological samples. The recombinant protein should match the epitope recognized by the capture and detection antibodies.

• Validation: It is essential to validate that the recombinant ACVR2B behaves identically to the native protein in your assay system. Differences in glycosylation, folding, or tag sequences can affect antibody recognition and quantification accuracy. You should confirm parallelism between the standard curve generated with recombinant ACVR2B and the response of endogenous ACVR2B in your sample matrix.

• Controls: Always include appropriate controls and calibrators in each assay run. If using recombinant ACVR2B as a standard, assign its value based on measurement in your ELISA, not solely on the mass stated on the vial, as immunoreactivity may differ.

• Limitations: If your ELISA is designed to quantify Activin A ligand (not the receptor), you must use Activin A standards, not ACVR2B. The receptor cannot substitute for the ligand as a calibrator due to distinct molecular structures and antibody specificities.

Best Practices:

• Use recombinant ACVR2B that is well-characterized (e.g., purity, molecular weight, activity, tag type).
• Validate the standard curve with serial dilutions and check for linearity and parallelism with native samples.
• Document any differences in recovery or sensitivity when switching between recombinant and native standards.

Summary Table:

In conclusion: You can use recombinant human Activin A receptor, type IIB as a standard for quantification in ELISA assays targeting ACVR2B, provided you validate its performance in your specific assay context. For assays quantifying Activin A ligand, use appropriate Activin A standards.

Recombinant Human Activin A receptor, type IIB (RIIB) has been validated for several key applications in published research, primarily related to its role in the activin signaling pathway and its therapeutic potential. The main applications include:

1. Muscle Mass and Strength Enhancement

   • Studies have shown that targeting ActRIIB (using recombinant forms or inhibitors) improves skeletal muscle mass and functional strength in mouse models of Duchenne muscular dystrophy (mdx mice). This is achieved by blocking ligands such as myostatin and activin A, which negatively regulate muscle growth.
   • Example: Treatment with a soluble ActRIIB-Fc fusion protein led to significant increases in body weight and lean muscle mass in mdx mice.

2. Bone Formation and Osteopenia/Sarcopenia Treatment

   • Inhibition of ActRIIB signaling has been shown to increase bone parameters, including bone volume, trabecular thickness, and trabecular number, in both healthy and immobilized mice. This suggests potential for treating osteoporosis and sarcopenia.

3. Hematopoiesis and Erythropoiesis

   • ActRIIB-Fc fusion proteins (e.g., Luspatercept) have been approved for treating anemia associated with β-thalassemia and myelodysplastic syndromes. These agents promote late-stage erythrocyte maturation by modulating the bone marrow microenvironment.

4. Biochemical and Binding Assays

   • Recombinant ActRIIB has been used in ELISA and surface plasmon resonance (SPR) assays to study its interaction with ligands such as Activin A, demonstrating high-affinity binding and enabling the development of inhibitors and therapeutic antibodies.

5. Therapeutic Antibody Development

   • Recombinant ActRIIB is used to generate and validate antibodies that block activin A-mediated signaling, with applications in treating diseases related to activin A activity, such as certain cancers and fibrotic disorders.

6. Signal Transduction Studies

   • ActRIIB is used in studies investigating the functional redundancy and signaling mechanisms of type I and type II receptors in the TGF-β superfamily, particularly in muscle and bone tissue.

In summary, recombinant Human Activin A receptor, type IIB (RIIB) has been validated for applications in muscle and bone biology, hematopoiesis, ligand binding assays, therapeutic antibody development, and signal transduction research.

To properly reconstitute and prepare Recombinant Human Activin A Receptor, Type IIB (RIIB) protein for cell culture experiments, follow these general guidelines based on standard protocols and manufacturer recommendations:

Reconstitution

1. Centrifuge the vial: Before opening, briefly centrifuge the lyophilized protein vial to ensure all powder is at the bottom.
2. Reconstitution buffer: Use sterile, endotoxin-free PBS (pH 7.2–7.4) or sterile distilled water, unless otherwise specified by the product datasheet. Some products may recommend PBS without calcium or magnesium.
3. Concentration: Reconstitute to a concentration between 0.1–1.0 mg/mL. For example:
   • For 100 µg of protein, add 100 µL to 1 mL of buffer.
   • For higher activity or specific assay requirements, follow the datasheet (some recommend 100 µg/mL).
4. Gentle mixing: Gently swirl or pipette up and down to dissolve the protein. Do not vortex or pipette vigorously to avoid denaturation.

Preparation for Cell Culture

1. Aliquot and store: After reconstitution, aliquot the protein solution to avoid repeated freeze-thaw cycles.
2. Storage:
   • Short-term: Store at 2–8°C for up to 1 week.
   • Long-term: Store at –20°C to –80°C for up to 3 months (check datasheet for exact stability).
3. Carrier protein (optional): For extended storage or to prevent adsorption, consider adding a carrier protein (e.g., 0.1% BSA, 5% HSA, or 5% trehalose), especially if the protein is carrier-free.
4. Sterility: Ensure all steps are performed under aseptic conditions for cell culture use.

Additional Notes

• Always refer to the Certificate of Analysis (CoA) or product datasheet for lot-specific instructions, as formulations may vary between suppliers.
• Avoid repeated freeze-thaw cycles to maintain protein activity.
• For functional assays, validate the protein activity using appropriate controls (e.g., binding or signaling assays).

By following these steps, you will ensure optimal solubility, stability, and biological activity of the Activin RIIB protein for your cell culture experiments.